178 related articles for article (PubMed ID: 15654351)
41. Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation.
Perruccio K; Topini F; Tosti A; Carotti A; Aloisi T; Aversa F; Martelli MF; Velardi A
Blood Cells Mol Dis; 2008; 40(1):76-83. PubMed ID: 17977031
[TBL] [Abstract][Full Text] [Related]
42. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study.
Barkholt L; Alici E; Conrad R; Sutlu T; Gilljam M; Stellan B; Christensson B; Guven H; Björkström NK; Söderdahl G; Cederlund K; Kimby E; Aschan J; Ringdén O; Ljunggren HG; Dilber MS
Immunotherapy; 2009 Sep; 1(5):753-64. PubMed ID: 20636021
[TBL] [Abstract][Full Text] [Related]
43. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms.
Murashige N; Kami M; Kishi Y; Kim SW; Takeuchi M; Matsue K; Kanda Y; Hirokawa M; Kawabata Y; Matsumura T; Kusumi E; Hirabayashi N; Nagafuji K; Suzuki R; Takeuchi K; Oshimi K
Br J Haematol; 2005 Aug; 130(4):561-7. PubMed ID: 16098071
[TBL] [Abstract][Full Text] [Related]
44. Tolerance in DLA-haploidentical canine littermates following CD6-depleted marrow transplantation and donor lymphocyte transfusion.
Zorn J; Herber M; Schwamberger S; Panzer W; Adler H; Kolb HJ
Exp Hematol; 2009 Aug; 37(8):998-1006. PubMed ID: 19446000
[TBL] [Abstract][Full Text] [Related]
45. Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation.
Vela-Ojeda J; García-Ruiz Esparza MA; Reyes-Maldonado E; Jiménez-Zamudio L; García-Latorre E; Moreno-Lafont M; Estrada-García I; Montiel-Cervantes L; Tripp-Villanueva F; Ayala-Sánchez M; García-León LD; Borbolla-Escoboza JR; Mayani H
Ann Hematol; 2006 Feb; 85(2):113-20. PubMed ID: 16311734
[TBL] [Abstract][Full Text] [Related]
46. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers.
Stern M; Passweg JR; Meyer-Monard S; Esser R; Tonn T; Soerensen J; Paulussen M; Gratwohl A; Klingebiel T; Bader P; Tichelli A; Schwabe D; Koehl U
Bone Marrow Transplant; 2013 Mar; 48(3):433-8. PubMed ID: 22941380
[TBL] [Abstract][Full Text] [Related]
47. At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies.
Locatelli F; Merli P; Rutella S
J Leukoc Biol; 2013 Dec; 94(6):1141-57. PubMed ID: 24096380
[TBL] [Abstract][Full Text] [Related]
48. High-dose iodine-131-metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma.
Toporski J; Garkavij M; Tennvall J; Ora I; Gleisner KS; Dykes JH; Lenhoff S; Juliusson G; Scheding S; Turkiewicz D; Békássy AN
Biol Blood Marrow Transplant; 2009 Sep; 15(9):1077-85. PubMed ID: 19660720
[TBL] [Abstract][Full Text] [Related]
49. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self.
Ruggeri L; Aversa F; Martelli MF; Velardi A
Immunol Rev; 2006 Dec; 214():202-18. PubMed ID: 17100886
[TBL] [Abstract][Full Text] [Related]
50. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
51. Non-CD34+ cells, especially CD8+ cytotoxic T cells and CD56+ natural killer cells, rather than CD34 cells, predict early engraftment and better transplantation outcomes in patients with hematologic malignancies after allogeneic peripheral stem cell transplantation.
Kim DH; Won DI; Lee NY; Sohn SK; Suh JS; Lee KB
Biol Blood Marrow Transplant; 2006 Jul; 12(7):719-28. PubMed ID: 16785061
[TBL] [Abstract][Full Text] [Related]
52. HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase.
Xiao-Jun H; Lan-Ping X; Kai-Yan L; Dai-Hong L; Huan C; Wei H; Yu-Hong C; Jing-Zhi W; Yao C; Xiao-Hui Z; Hong-Xia S; Dao-Pei L
Ann Med; 2008; 40(6):444-55. PubMed ID: 18608121
[TBL] [Abstract][Full Text] [Related]
53. Suppression of graft-versus-host disease after adoptive infusion of alloreactive NK cells induced by silencing Ly49C gene in mice.
Cao D; Hu L; Wang Y; Wang L; Zheng W; Ma W
Transpl Immunol; 2009 Mar; 20(4):243-8. PubMed ID: 19010415
[TBL] [Abstract][Full Text] [Related]
54. KIR matching in hematopoietic stem cell transplantation.
Bignon JD; Gagne K
Curr Opin Immunol; 2005 Oct; 17(5):553-9. PubMed ID: 16085405
[TBL] [Abstract][Full Text] [Related]
55. Preservation of immune repertoire by selective depletion of haploidentical grafts.
Guinan E; Luzmik L; Handgretinger R; Woolfrey A
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S68-74. PubMed ID: 19941966
[TBL] [Abstract][Full Text] [Related]
56. Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation.
Micklethwaite K; Hansen A; Foster A; Snape E; Antonenas V; Sartor M; Shaw P; Bradstock K; Gottlieb D
Biol Blood Marrow Transplant; 2007 Jun; 13(6):707-14. PubMed ID: 17531781
[TBL] [Abstract][Full Text] [Related]
57. NK cell receptors as tools in cancer immunotherapy.
Sentman CL; Barber MA; Barber A; Zhang T
Adv Cancer Res; 2006; 95():249-92. PubMed ID: 16860660
[TBL] [Abstract][Full Text] [Related]
58. Immune restoration following hematopoietic stem cell transplantation: an evolving target.
Auletta JJ; Lazarus HM
Bone Marrow Transplant; 2005 May; 35(9):835-57. PubMed ID: 15778723
[TBL] [Abstract][Full Text] [Related]
59. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
60. The activating killer cell immunoglobulin-like receptors as important determinants of acute graft-versus host disease in hematopoietic stem cell transplantation for acute myelogenous leukemia.
Kim HJ; Choi Y; Min WS; Kim TG; Cho BS; Kim SY; Eom KS; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Kim CC
Transplantation; 2007 Nov; 84(9):1082-91. PubMed ID: 17998861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
